Concomitant radiotherapy with temozolomide significantly improves PFS in IDH-wildtype glioblastoma patients compared to radiotherapy alone. The study involved 244 patients, with 72.5% receiving ...

Thalidomide at a dose of 400 mg/d was well tolerated in patients younger than 70, and 200 mg/d was well tolerated in older patients. The most common adverse events were grade 2 or 3 constipation and ...

Building a Protocol Expressway: The Case of Mayo Clinic Cancer Center Eighty-five eligible patients were enrolled; 42 were randomly assigned to dose-dense and 43 to metronomic temozolomide. The 1-year ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Temozolomide with radiation therapy improved 5- and ...

Allarity Therapeutics has announced a Phase 2 clinical trial to evaluate the combination of stenoparib, a dual PARP/Wnt pathway inhibitor, with temozolomide for patients with recurrent Small Cell Lung ...

Adjuvant temozolomide (12 cycles, 5/28-day schedule) after radiotherapy significantly improves overall survival in IDH-mutant, 1p/19q non-codeleted anaplastic astrocytoma compared with radiotherapy ...

Glioblastoma is the most aggressive primary brain cancer in adults, killing most patients within two years of diagnosis ...

Rashmi Chugh, MD, discusses the early outcomes of a trial of ozekibart plus chemotherapy in Ewing sarcoma. Rashmi Chugh, MD, ...

In this phase 1 trial (NCT03715933), ozekibart is paired with the established chemotherapy duo of temozolomide and irinotecan ...

Trial to explore novel combination therapy for patients with recurrent Small Cell Lung Cancer who have failed frontline treatment Fully funded by the U.S. Veterans’ Administration Special Emphasis ...